Circle Pharma has raised $66 million to take cyclin-targeted programs toward clinical development. The Eli Lilly-backed series C round sets Circle up to build on its years of research into cell-permeable macrocyclic peptide therapeutics with the potential to hit previously undruggable targets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,